[A20-100] Ivacaftor (cystic fibrosis, 4 to < 6 months, gating mutation) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2021
Commission awarded on 27.11.2020 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Patients with cystic fibrosis from 4 to < 6 months of age and weighing 5 kg or more who have one of the following gating (class III) mutations in the CFTR gene: G551D, G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N or S549R
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.